GLP-1 Formula to boost GLP-1 and improve blood sugar control
Official title: Exploring the Effects of GLP-1 Formula on GLP-1 Secretion and Postprandial Glucose Regulation
Run by Chung Shan Medical University · NCT07082062 · Data updated 2026-11-12
This will test whether a multi-ingredient GLP-1 dietary supplement can raise GLP-1 levels and improve blood sugar and insulin responses in adults with higher body fat.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Chung Shan Medical University Academic / other |
| Locations | 1 site (Taichung) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | October 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | July 24, 2025 |
| Trial ID | NCT07082062 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–50 years old with body fat percentage over 25% who are not pregnant or breastfeeding and have no diabetes, major gastrointestinal disease, recent probiotic or weight-loss product use, or prior gastrointestinal surgery.
✕Probably not a fit
People with diabetes, autoimmune disease, chronic gastrointestinal disorders, prior gastrointestinal surgery, lactose intolerance, recent use of probiotics or weight-loss products, or who are pregnant or breastfeeding are excluded and unlikely to receive benefit from joining this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, crossover investigation tests a multi-component oral GLP-1 Formula containing a probiotic (Bifidobacterium breve), a prebiotic blend (including kombucha extract, soy peptide, L‑arabinose, erythritol), and rocket apple extract for effects on incretin and glycemic responses. The study is split into two parallel crossover trials of about 50 participants each: one measuring acute changes in circulating GLP-1 after a single dose and the other measuring postprandial glucose and insulin responses. Participants attend two intervention visits per trial with at least a one-month washout if enrolled in both trials; each visit involves fasting and serial post-meal blood sampling over roughly six hours and appetite assessments. The trial enrolls healthy adults 18–50 years with body fat >25% and excludes people with diabetes, major GI disorders, recent probiotic or weight-loss supplement use, pregnancy, or prior GI surgery.
Why it matters
Potential benefit: If successful, the formula could increase endogenous GLP-1 secretion and improve post-meal glucose and insulin control, potentially supporting metabolic health in overweight adults.
How similar studies have gone: Some prior studies of specific probiotics or prebiotics have shown modest effects on incretin hormones and postprandial glucose, but this exact multi-component GLP-1 Formula is novel and not widely tested in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female participants aged 18-50 years with a body fat percentage greater than 25%. Exclusion Criteria: * Use of probiotics, weight loss products, or gastrointestinal health-related supplements or medications within the past month. * Presence of diabetes, autoimmune diseases, cancer, chronic gastrointestinal disorders, lactose intolerance, or chronic diarrhea. * History of gastrointestinal surgery. * Pregnant or breastfeeding women.
Where it's running
-
Chung Shan Medical University Hospital
Taichung, Taiwan Recruiting
Study contacts
- Principal investigator: Shih-Chien Huang, PhD, Associate Professor — Chung Shan Medical University
- Study coordinator: Shih-Chien Huang, PhD, Associate Professor
- Email: schuang@csmu.edu.tw
- Phone: +886424730022
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Concurrent exercise program changes PCSK9 in adults with overweight
A supervised program of aerobic plus resistance training for eight weeks will test whether it lowers PCSK9 levels in adults who are overweight.
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese
This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.
-
FutureShape Family: a family-based weight-management program with semaglutide for children and parents
This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.